The global CAR-T Therapy for Hematological Cancer market  size is set to grow from  US$ 5299 million in 2024 to US$ 22200 million in 2030; it is expected to grow at a CAGR of 27.0% from 2024 to 2030.

Global CAR-T Therapy for Hematological Cancer Market Growth and Outlook 2025-31

The global CAR-T Therapy for Hematological Cancer market size is predicted to grow from US$ 5299 million in 2024 to US$ 22200 million in 2030; it is expected to grow at a CAGR of 27.0% from 2024 to 2030. CAR-T (Chimeric Antigen Receptor T-cell) therapy is a cutting-edge immunotherapy for hematological cancers, involving the genetic modification of a patients T cells to express synthetic receptors targeting specific antigens on cancer cells. These engineered T cells are expanded in the lab and reintroduced into the patient, where they can recognize and destroy cancerous cells with high specificity. Key features include its remarkable efficacy in treating certain blood cancers like B-cell lymphomas, leukemias, and multiple myeloma, particularly in patients with relapsed or refractory disease, and its potential for long-term remission. CAR-T therapy is primarily applied in advanced hematological malignancies and is being explored for broader indications through ongoing clinical trials. Despite its promise, challenges such as high cost, manufacturing complexity, and management of severe side effects like cytokine release syndrome (CRS) remain areas of active research. United States market for CAR-T Therapy for Hematological Cancer is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030. China market for CAR-T Therapy for Hematological Cancer is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030. Europe market for CAR-T Therapy for Hematological Cancer is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030. Global key CAR-T Therapy for Hematological Cancer players cover Novartis, Gilead Sciences, Bristol-Myers Squibb, J&J, JW Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023. LPI (LP Information) newest research report, the CAR-T Therapy for Hematological Cancer Industry Forecast looks at past sales and reviews total world CAR-T Therapy for Hematological Cancer sales in 2023, providing a comprehensive analysis by region and market sector of projected CAR-T Therapy for Hematological Cancer sales for 2024 through 2030. With CAR-T Therapy for Hematological Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR-T Therapy for Hematological Cancer industry. This Insight Report provides a comprehensive analysis of the global CAR-T Therapy for Hematological Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on CAR-T Therapy for Hematological Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global CAR-T Therapy for Hematological Cancer market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR-T Therapy for Hematological Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR-T Therapy for Hematological Cancer. This report presents a comprehensive overview, market shares, and growth opportunities of CAR-T Therapy for Hematological Cancer market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Target: CD19 &nbsp;&nbsp;&nbsp; Target: BCMA &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Lymphoma &nbsp;&nbsp;&nbsp; Multiple Myeloma &nbsp;&nbsp;&nbsp; Leukemia This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Novartis &nbsp;&nbsp;&nbsp; Gilead Sciences &nbsp;&nbsp;&nbsp; Bristol-Myers Squibb &nbsp;&nbsp;&nbsp; J&J &nbsp;&nbsp;&nbsp; JW Therapeutics &nbsp;&nbsp;&nbsp; FOSUNKite

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global CAR-T Therapy for Hematological Cancer Market Size 2019-2030 &nbsp;2.1.2 CAR-T Therapy for Hematological Cancer Market Size CAGR by Region (2019 VS 2023 VS 2030) &nbsp;2.1.3 World Current & Future Analysis for CAR-T Therapy for Hematological Cancer by Country/Region, 2019, 2023 & 2030 &nbsp;2.2 CAR-T Therapy for Hematological Cancer Segment by Type &nbsp;2.2.1 Target: CD19 &nbsp;2.2.2 Target: BCMA &nbsp;2.2.3 Others &nbsp;2.3 CAR-T Therapy for Hematological Cancer Market Size by Type &nbsp;2.3.1 CAR-T Therapy for Hematological Cancer Market Size CAGR by Type (2019 VS 2023 VS 2030) &nbsp;2.3.2 Global CAR-T Therapy for Hematological Cancer Market Size Market Share by Type (2019-2024) &nbsp;2.4 CAR-T Therapy for Hematological Cancer Segment by Application &nbsp;2.4.1 Lymphoma &nbsp;2.4.2 Multiple Myeloma &nbsp;2.4.3 Leukemia &nbsp;2.5 CAR-T Therapy for Hematological Cancer Market Size by Application &nbsp;2.5.1 CAR-T Therapy for Hematological Cancer Market Size CAGR by Application (2019 VS 2023 VS 2030) &nbsp;2.5.2 Global CAR-T Therapy for Hematological Cancer Market Size Market Share by Application (2019-2024) 3 CAR-T Therapy for Hematological Cancer Market Size by Player &nbsp;3.1 CAR-T Therapy for Hematological Cancer Market Size Market Share by Player &nbsp;3.1.1 Global CAR-T Therapy for Hematological Cancer Revenue by Player (2019-2024) &nbsp;3.1.2 Global CAR-T Therapy for Hematological Cancer Revenue Market Share by Player (2019-2024) &nbsp;3.2 Global CAR-T Therapy for Hematological Cancer Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 CAR-T Therapy for Hematological Cancer by Region &nbsp;4.1 CAR-T Therapy for Hematological Cancer Market Size by Region (2019-2024) &nbsp;4.2 Global CAR-T Therapy for Hematological Cancer Annual Revenue by Country/Region (2019-2024) &nbsp;4.3 Americas CAR-T Therapy for Hematological Cancer Market Size Growth (2019-2024) &nbsp;4.4 APAC CAR-T Therapy for Hematological Cancer Market Size Growth (2019-2024) &nbsp;4.5 Europe CAR-T Therapy for Hematological Cancer Market Size Growth (2019-2024) &nbsp;4.6 Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size Growth (2019-2024) 5 Americas &nbsp;5.1 Americas CAR-T Therapy for Hematological Cancer Market Size by Country (2019-2024) &nbsp;5.2 Americas CAR-T Therapy for Hematological Cancer Market Size by Type (2019-2024) &nbsp;5.3 Americas CAR-T Therapy for Hematological Cancer Market Size by Application (2019-2024) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC CAR-T Therapy for Hematological Cancer Market Size by Region (2019-2024) &nbsp;6.2 APAC CAR-T Therapy for Hematological Cancer Market Size by Type (2019-2024) &nbsp;6.3 APAC CAR-T Therapy for Hematological Cancer Market Size by Application (2019-2024) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe CAR-T Therapy for Hematological Cancer Market Size by Country (2019-2024) &nbsp;7.2 Europe CAR-T Therapy for Hematological Cancer Market Size by Type (2019-2024) &nbsp;7.3 Europe CAR-T Therapy for Hematological Cancer Market Size by Application (2019-2024) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa CAR-T Therapy for Hematological Cancer by Region (2019-2024) &nbsp;8.2 Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size by Type (2019-2024) &nbsp;8.3 Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size by Application (2019-2024) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global CAR-T Therapy for Hematological Cancer Market Forecast &nbsp;10.1 Global CAR-T Therapy for Hematological Cancer Forecast by Region (2025-2030) &nbsp;10.1.1 Global CAR-T Therapy for Hematological Cancer Forecast by Region (2025-2030) &nbsp;10.1.2 Americas CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.1.3 APAC CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.1.4 Europe CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.1.5 Middle East & Africa CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.2 Americas CAR-T Therapy for Hematological Cancer Forecast by Country (2025-2030) &nbsp;10.2.1 United States Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.2.2 Canada Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.2.3 Mexico Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.2.4 Brazil Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.3 APAC CAR-T Therapy for Hematological Cancer Forecast by Region (2025-2030) &nbsp;10.3.1 China CAR-T Therapy for Hematological Cancer Market Forecast &nbsp;10.3.2 Japan Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.3.3 Korea Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.3.4 Southeast Asia Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.3.5 India Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.3.6 Australia Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.4 Europe CAR-T Therapy for Hematological Cancer Forecast by Country (2025-2030) &nbsp;10.4.1 Germany Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.4.2 France Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.4.3 UK Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.4.4 Italy Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.4.5 Russia Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.5 Middle East & Africa CAR-T Therapy for Hematological Cancer Forecast by Region (2025-2030) &nbsp;10.5.1 Egypt Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.5.2 South Africa Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.5.3 Israel Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.5.4 Turkey Market CAR-T Therapy for Hematological Cancer Forecast &nbsp;10.6 Global CAR-T Therapy for Hematological Cancer Forecast by Type (2025-2030) &nbsp;10.7 Global CAR-T Therapy for Hematological Cancer Forecast by Application (2025-2030) &nbsp;10.7.1 GCC Countries Market CAR-T Therapy for Hematological Cancer Forecast 11 Key Players Analysis &nbsp;11.1 Novartis &nbsp;11.1.1 Novartis Company Information &nbsp;11.1.2 Novartis CAR-T Therapy for Hematological Cancer Product Offered &nbsp;11.1.3 Novartis CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2019-2024) &nbsp;11.1.4 Novartis Main Business Overview &nbsp;11.1.5 Novartis Latest Developments &nbsp;11.2 Gilead Sciences &nbsp;11.2.1 Gilead Sciences Company Information &nbsp;11.2.2 Gilead Sciences CAR-T Therapy for Hematological Cancer Product Offered &nbsp;11.2.3 Gilead Sciences CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2019-2024) &nbsp;11.2.4 Gilead Sciences Main Business Overview &nbsp;11.2.5 Gilead Sciences Latest Developments &nbsp;11.3 Bristol-Myers Squibb &nbsp;11.3.1 Bristol-Myers Squibb Company Information &nbsp;11.3.2 Bristol-Myers Squibb CAR-T Therapy for Hematological Cancer Product Offered &nbsp;11.3.3 Bristol-Myers Squibb CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2019-2024) &nbsp;11.3.4 Bristol-Myers Squibb Main Business Overview &nbsp;11.3.5 Bristol-Myers Squibb Latest Developments &nbsp;11.4 J&J &nbsp;11.4.1 J&J Company Information &nbsp;11.4.2 J&J CAR-T Therapy for Hematological Cancer Product Offered &nbsp;11.4.3 J&J CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2019-2024) &nbsp;11.4.4 J&J Main Business Overview &nbsp;11.4.5 J&J Latest Developments &nbsp;11.5 JW Therapeutics &nbsp;11.5.1 JW Therapeutics Company Information &nbsp;11.5.2 JW Therapeutics CAR-T Therapy for Hematological Cancer Product Offered &nbsp;11.5.3 JW Therapeutics CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2019-2024) &nbsp;11.5.4 JW Therapeutics Main Business Overview &nbsp;11.5.5 JW Therapeutics Latest Developments &nbsp;11.6 FOSUNKite &nbsp;11.6.1 FOSUNKite Company Information &nbsp;11.6.2 FOSUNKite CAR-T Therapy for Hematological Cancer Product Offered &nbsp;11.6.3 FOSUNKite CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2019-2024) &nbsp;11.6.4 FOSUNKite Main Business Overview &nbsp;11.6.5 FOSUNKite Latest Developments 12 Research Findings and Conclusion

Report	Global CAR-T Therapy for Hematological Cancer Market Growth (Status and Outlook) 2024-2030
Selected License	Multi ID: LPI16052

Buyer Information

Order Summary